Attovia Therapeutics, Inc.
NASDAQ:ATTOBiotechnology
-$0.18 today
- Market cap
- $709.92M
- Beta
- 0.00
- P/E (TTM)
- -15.9
- EPS (TTM)
- -$0.86
Volume 0.34M
Average 0.45M
ATTO Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
Attovia Therapeutics, Inc.NASDAQ: ATTO
Net Change in Cash · Q2 FY2026 · quarter ended Jun 2026
Net change in cash of -$10.47M in Q2 FY2026
Q2 FY2026 net change in cash was -$10.47M.
Context
- Net change in cash amounted to 708.2% of revenue in FY2025.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
USD · from the cash flow
- Latest · FY2025
- 9.56M USD
- Year-over-year change
- -68.8%
- 1-year CAGR
- -68.8%
| Period | Period end | Net Change in Cash | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 9.56M | -68.8% |
| FY2024 | 2024-12-31 | 30.63M | — |
Net Change in Cash vs competitors
How ATTO compares with its peers on the latest reported figures
- ATTO's FY2025 net change in cash of $9.56M is the 9th largest of the 10 companies compared; the peer median is $26.92M.
- Its year-over-year change of -68.8% is the 7th highest of 9, against a peer median of +79.9%.
- Net change in cash amounts to 708.2% of revenue for ATTO, versus a peer median of 245.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $149.83M | +233.4% | — | 64.5% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $100.27M | +131.4% | +10.3% | — |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $88.34M | +2748.7% | +2.1% | 1194.1% |
ZURAZura Bio Limited | LTM Mar 2026 | $55.03M | -31.9% | — | — |
EVMNEvommune, Inc. | LTM Mar 2026 | $42.61M | — | — | 426.1% |
| FY2025 | $39.89M | +45.4% | -38.2% | 62323.4% | |
| LTM Mar 2026 | $26.92M | +114.4% | +69.8% | — | |
| LTM Mar 2026 | $14.73M | -70.6% | — | 27.4% | |
| FY2025 | $9.56M | -68.8% | — | 708.2% | |
| LTM Mar 2026 | $1.7M | -69.1% | — | 20.3% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
| Peer median (excluding ATTO) | $26.92M | +79.9% | +6.2% | 245.3% | |
Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|
| Net Income | (45.05M) | (60.9M) |
| Depreciation & Amortization | 313K | 804K |
| Deferred Income Tax | 0 | 0 |
| Stock-Based Compensation | 0 | 0 |
| Change in Working Capital | 1.54M | 276K |
| Accounts Receivables | 0 | 0 |
| Inventory | 0 | 0 |
| Accounts Payables | 1.72M | 180K |
| Other Working Capital | (181K) | 96K |
| Other Non-Cash Items | 8.16M | 619K |
| Operating Cash Flow | (35.04M) | (59.2M) |
| Capital Expenditures | (1.77M) | (2.31M) |
| Acquisitions (Net) | 0 | 0 |
| Purchases of Investments | (46.03M) | (221.89M) |
| Sales of Investments | 8M | 150.75M |
| Other Investing Activities | 0 | 0 |
| Investing Cash Flow | (39.8M) | (73.46M) |
| Debt Repayment | (171K) | 0 |
| Common Stock Issued | 82.92M | 142.01M |
| Common Stock Repurchased | 0 | 0 |
| Dividends Paid | 0 | 0 |
| Other Financing Activities | 0 | 0 |
| Financing Cash Flow | 82.75M | 142.01M |
| Effect of Forex Changes | 22.73M | 203K |
| Net Change in Cash | 30.63M | 9.56M |
| Free Cash Flow | (36.81M) | (61.51M) |
Attovia Therapeutics, Inc.
NASDAQ:ATTO
Intrinsic Alpha fair value
Locked
Current Price
$15.53
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.